Business
NAMCP Independent Third-Party Review Validates Value Proposition of iRhythm Zio XT Service to Health Systems and Payers
Zio XT value proposition lives up to its claims and demonstrates high value around clinical utility and payer economics SAN FRANCISCO, July 18, 2023 (GLOBE
About this update from Irhythm Holdings, Inc.
[{"type":"text","content":"Zio XT value proposition lives up to its claims and demonstrates high value around clinical utility and payer economics\nSAN FRANCISCO, July 18, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced that an independent third-party review, conducted by the National Association of Managed Care Physicians (NAMCP), validated evidence that shows the Zio XT long-term cardiac monitoring service contributes value to health systems and payers. Relative to efficacy and clinical utility, the assessment validated evidence on Zio XT’s diagnostic yield, analyzable wear time, detection of many types of arrhythmias, lower likelihood of retesting compared with other monitor types, improved clinical outcomes, and decreased time to diagnosis. Relative to patient compliance, the assessment validated that multiple studies show high patient compliance as demonstrated by long median and mean wear time, and further noted that published studies have reported patients preferred the Zio XT over the conventional Holter monitor and found the device comfortable to wear. “As a clinician-led organization committed to delivering evidence-based solutions for payers and providers, this independent assessment reinforces our belief in the value proposition of our Zio XT service,” said Quentin Blackford, iRhythm President and Chief Executive Officer. “As iRhythm works to advance the standards of cardiac care, we are proud to be selected by the NAMCP as the first healthcare solution to go through this evaluation.” The independent review, led by the NAMCP’s Organization for Objective Review and Clinical Assessment (OORCA), is groundbreaking as a first for ambulatory cardiac monitoring in the value-based care environment. It is a path forward for health systems and payers who find themselves tasked with not only improving patient outcomes but also managing the costs of healthcare resource utilization. “Finding opportunities to educate medical directors of health plans and provider systems continues to be our mission, and we are now in a place to do that in a new way. iRhythm’s Zio XT service has been through the OORCA assessment and is now validated as the first solution of its kind to bring clear benefits from an objective point...